| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
CGEM
Cullinan Management
|
Oct 27, 2026 | BUY |
Strong Buy
+135.1% avg upside
16 analysts
|
$41.00
172.74% Upside
|
-30.7% | Β· |
|
JBIO
Jade Biosciences
|
Oct 26, 2026 | BUY |
Strong Buy
+312.1% avg upside
17 analysts
|
$77.00
447.68% Upside
|
+11.3% | Β· |
|
ORKA
Oruka Therapeutics
|
Oct 26, 2026 | BUY |
Strong Buy
+37.2% avg upside
16 analysts
|
$151.00
55.80% Upside
|
+16.4% | Β· |
|
AVTX
Avalo Therapeutics
|
Oct 23, 2026 | BUY |
Strong Buy
+561.5% avg upside
20 analysts
|
$10.00
39.57% Upside
|
+12.0% | Β· |
|
SYRE
Spyre Therapeutics
|
Oct 19, 2026 | BUY |
Strong Buy
+0.9% avg upside
25 analysts
|
$121.00
25.32% Upside
|
+22.8% | Β· |
|
RZLT
Rezolute
|
Oct 14, 2026 | BUY |
Strong Buy
+197.4% avg upside
14 analysts
|
$6.00
51.86% Upside
|
-13.6% | Β· |
|
LQDA
Liquidia Technologies
|
Oct 14, 2026 | BUY |
Strong Buy
+0.7% avg upside
15 analysts
|
$70.00
55.39% Upside
|
+69.2% | Β· |
|
NKTR
Nektar Therapeutics
|
Oct 09, 2026 | BUY |
Buy
+97.0% avg upside
26 analysts
|
$178.00
357.92% Upside
|
-9.1% | Β· |
|
CLYM
Climb Bio
|
Oct 01, 2026 | BUY |
Strong Buy
+120.9% avg upside
21 analysts
|
$32.00
212.28% Upside
|
-7.0% | Β· |
|
ABVX
Abivax SA Sponsored ADR
|
Oct 01, 2026 | BUY |
Strong Buy
+54.7% avg upside
16 analysts
|
$175.00
102.09% Upside
|
-7.9% | Β· |
|
UTHR
United Therapeutics
|
Oct 01, 2026 | BUY |
Buy
-22.7% avg upside
27 analysts
|
$728.00
21.59% Upside
|
+3.5% | Β· |
|
RNAC
Cartesian Therapeutics
|
Sep 29, 2026 | BUY |
Strong Buy
+378.5% avg upside
19 analysts
|
$44.00
577.89% Upside
|
-4.8% | Β· |
|
MAZE
Maze Therapeutics, Inc.
|
Sep 22, 2026 | BUY |
Strong Buy
+102.8% avg upside
14 analysts
|
$46.00
46.06% Upside
|
+21.0% | Β· |
|
AKBA
Akebia Therapeutics
|
Sep 14, 2026 | BUY |
Buy
+1184.8% avg upside
16 analysts
|
$4.00
466.18% Upside
|
-58.4% | Β· |
|
CNTB
Connect Biopharma Holdings
|
Aug 27, 2026 | BUY |
Strong Buy
+718.8% avg upside
12 analysts
|
$10.00
1146.60% Upside
|
-69.7% | Β· |
|
TVRD
Tvardi Therapeutics
|
Aug 19, 2026 | BUY |
Buy
+2090.0% avg upside
24 analysts
|
$5.00
530.73% Upside
|
-25.0% | Β· |
|
OTLK
Outlook Therapeutics
|
Aug 14, 2026 | BUY |
Buy
+1882.0% avg upside
11 analysts
|
$4.00
754.56% Upside
|
-42.3% | Β· |
|
MLTX
MoonLake Immunotherapeutics
|
Aug 10, 2026 | BUY |
Strong Buy
+158.9% avg upside
20 analysts
|
$30.00
154.76% Upside
|
-27.9% | Β· |
|
INVA
Innoviva
|
Aug 05, 2026 | BUY |
Buy
+37.9% avg upside
13 analysts
|
$42.00
98.02% Upside
|
-7.2% | Β· |
|
YARW
Yarrow Bioscience
|
Aug 03, 2026 | BUY |
Strong Buy
+38.5% avg upside
9 analysts
|
$58.00
191.43% Upside
|
-46.3% | Β· |
|
MREO
Mereo Biopharma Group Plc
|
Mar 19, 2026 | BUY |
Buy
+1238.5% avg upside
11 analysts
|
$1.00
245.50% Upside
|
-16.7% | Β· |
|
ARDX
Ardelyx
|
Feb 20, 2026 | BUY |
Strong Buy
+324.3% avg upside
21 analysts
|
$17.00
461.03% Upside
|
-46.1% | Β· |
|
VRDN
Viridian Therapeutics
|
Nov 04, 2025 | BUY |
Strong Buy
+42.6% avg upside
32 analysts
|
$61.00
147.23% Upside
|
+28.9% | Β· |
|
PTGX
Protagonist Therapeutics
|
Nov 03, 2025 | BUY |
Strong Buy
-17.0% avg upside
19 analysts
|
$82.00
43.43% Downside
|
+84.7% | Β· |
|
RANI
Rani Therapeutics Holdings
|
Mar 31, 2025 | BUY |
Strong Buy
+1444.2% avg upside
10 analysts
|
$14.00
2272.93% Upside
|
-41.3% | Β· |
|
ZLDPF
Zealand Pharma
|
Mar 17, 2025 | BUY |
Buy
+137.6% avg upside
12 analysts
|
$157.36
375.66% Upside
|
-51.5% | Β· |
|
KROS
Keros Therapeutics
|
Dec 12, 2024 | HOLD |
Strong Buy
+116.6% avg upside
21 analysts
|
β | +16.7% | Β· |
|
ANAB
AnaptysBio
|
Dec 02, 2024 | HOLD |
Strong Buy
+48.7% avg upside
26 analysts
|
β | +67.8% | Β· |
|
ACRS
Aclaris Therapeutics
|
Nov 18, 2024 | BUY |
Strong Buy
+155.5% avg upside
16 analysts
|
$8.00
101.58% Upside
|
-20.7% | Β· |
|
AURA
Aura Biosciences Inc
|
Nov 13, 2024 | BUY |
Strong Buy
+230.6% avg upside
9 analysts
|
$24.00
290.95% Upside
|
-46.5% | Β· |
|
MTNB
Matinas BioPharma
|
Nov 09, 2023 | BUY |
Strong Buy
+817.2% avg upside
7 analysts
|
$50.00
3211.18% Upside
|
-94.2% | Β· |
|
BIORQ
Biora Therapeutics
|
May 03, 2022 | BUY |
Strong Buy
+22439999900.0% avg upside
7 analysts
|
$4.00
399999899.93% Upside
|
Β· | Β· |
|
VKTX
Viking Therapeutics
|
Apr 28, 2021 | BUY |
Strong Buy
+172.0% avg upside
31 analysts
|
$12.00
56.08% Downside
|
-62.0% | Β· |
|
ALDX
Aldeyra Therapeutics
|
Apr 27, 2021 | BUY |
Strong Buy
+2746.2% avg upside
21 analysts
|
$29.00
5075.77% Upside
|
-77.3% | Β· |
|
PLRX
Pliant Therapeutics
|
Apr 20, 2021 | BUY |
Buy
+2494.5% avg upside
21 analysts
|
$51.00
5837.90% Upside
|
Β· | Β· |
|
WHWK
Whitehawk Therapeutics
|
Dec 09, 2020 | BUY |
Strong Buy
+274.2% avg upside
15 analysts
|
$60.00
1751.80% Upside
|
-27.5% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.